Study guide
3.4 Antimicrobial & Biofilm Dressings: Silver, Cadexomer Iodine, and Honey
NAWCCB WCC Wound Care Certified Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
About the NAWCCB WCC Exam How to Use This Study Guide
2 Assessment: Skin & Tissue Foundations
1.1 Skin Anatomy, Physiology, and Barrier Function 1.2 Phases of Wound Healing & Cellular Events 1.3 Acute vs. Chronic Wounds & Etiology Classification 1.4 TIME and MEASURE Assessment Frameworks 1.5 Wound Bed Tissue Types & Periwound Assessment 1.6 Pain Assessment: Scales, Wound Pain Types, and Procedural Analgesia 1.7 Psychosocial History, Cognitive Status, and Functional Assessment 1.8 Skin Integrity Across the Lifespan: Neonatal, Pediatric, Adult, and Geriatric
3 Assessment: Diagnostic Tools & Risk Assessment
2.1 Vascular Assessment: ABI, TcPO2, and Arterial/Venous Doppler 2.2 Neuropathy & Monofilament Testing in Diabetic Patients 2.3 Pressure Injury Risk Assessment: Braden Scale Subscales & Scoring 2.4 NPIAP Pressure Injury Staging (Stages 1-4, Unstageable, DTPI) 2.5 Exudate Characterization, Biofilm (NERDS/STONEES), & Wound Culture 2.6 Laboratory Interpretation in Wound Care: Albumin, Prealbumin, ESR, A1C, CBC, and CMP 2.7 Risk Assessment Instruments Beyond Braden: Norton, Braden Q, Braden QD, Wagner, and University of Texas
4 Treatment: Dressing Selection & Debridement Modalities
3.1 Principles of Dressing Selection by Exudate & Moisture Balance 3.2 High-Absorbency Dressings: Alginates, Hydrofibers, and Foams 3.3 Barrier & Hydrating Dressings: Hydrocolloids, Transparent Films, and Hydrogels 3.4 Antimicrobial & Biofilm Dressings: Silver, Cadexomer Iodine, and Honey 3.5 Debridement Modalities: Sharp, Enzymatic, Autolytic, Mechanical, & Biosurgical
5 Treatment: Advanced Therapies & Specialized Management
4.1 Negative Pressure Wound Therapy (NPWT) Indications, Settings, & Precautions 4.2 Compression Therapy Protocols & ABI Safety Cutoffs 4.3 DFU Off-loading Hierarchy: TCC, RCW, and Therapeutic Footwear 4.4 Support Surfaces, Microclimate Control, & Repositioning Protocols 4.5 Advanced Biologics, Cellular/Tissue Products (CTPs), & HBOT
6 Reevaluation & Wound Healing Trajectory
5.1 Healing Trajectory Benchmarks & Percent Area Reduction (PAR) 5.2 Serial Wound Measurement, Depth Profiling, & Digital Photography 5.3 Treatment Plan Reassessment & Non-Healing Wound Escalation Triggers 5.4 Biofilm Progression & Systemic Infection Re-evaluation 5.5 Palliative Wound Management: Odor, Exudate, and Pain Control 5.6 Validated Healing Instruments: The PUSH Tool, BWAT, and Evaluating Adherence
7 Risk Reduction & Prevention Strategies
6.1 Pressure Injury Prevention: Bundles, Turning Schedules, & Heel Floating 6.2 Moisture-Associated Skin Damage (MASD) & Incontinence-Associated Dermatitis (IAD) 6.3 Infection Control, Contact Precautions, & Environmental Hygiene 6.4 Prevention of Skin Tears & Medical Adhesive-Related Skin Injuries (MARSI) 6.5 Diabetic & Venous Ulcer Recurrence Prevention Protocols 6.6 At-Risk Populations: Spinal Cord Injury, Stroke, Critical Care, and Cognitive Impairment
8 Patient & Caregiver Education
7.1 Patient & Caregiver Wound Care Teaching & Self-Management 7.2 Diabetic Foot Self-Inspection & Footwear Education 7.3 Nutritional Assessment & Dietary Interventions for Wound Healing 7.4 Off-loading Compliance & Patient Mobility Education 7.5 Recognizing Complications, Infection Signs, & When to Seek Care 7.6 Educating the Interprofessional Team & Developing Educational Media
9 Administration & Program Management
8.1 Wound Care Documentation Standards & Clinical Records 8.2 Admission Wound Screening & Present on Admission (POA) Documentation 8.3 Interdisciplinary Team Roles & Clinical Care Coordination 8.4 Quality Improvement Metrics & HAPI Tracking Programs 8.5 Wound Care Formulary Management & Resource Utilization
10 Legal, Ethical, & Scope of Practice
9.1 Informed Consent, Treatment Refusal, & Autonomy in Wound Care 9.2 HIPAA Compliance & Clinical Photography Privacy Standards 9.3 Scope of Practice Across WCC-Eligible Professions (RN, LPN, PT, OT, DPM, MD/DO, PA) 9.4 HAPI Malpractice Liability & Documentation Defense 9.5 Ethical Considerations in Non-Healing Wounds & End-of-Life Skin Care 9.6 Regulatory Compliance, Coding Standards, & Audit Protection
3.4 Antimicrobial & Biofilm Dressings: Silver, Cadexomer Iodine, and Honey
Key Takeaways Explain This Topic AI
Antimicrobial dressings are indicated when clinical signs of localized bioburden (NERDS criteria) or systemic infection (STONEES criteria) are present; routine use on clean, healing wounds is inappropriate.
Ionic silver ( A g + Ag^+ A g + ) dressings provide broad-spectrum bactericidal activity by damaging cell walls, denaturing enzymes, and disrupting bacterial DNA, with sustained release over 3-7 days.
Cadexomer iodine consists of 0.9% elemental iodine in starch micro-beads; it provides slow sustained release that penetrates and disrupts mature bacterial biofilms without host cytotoxicity.
Medical-grade Leptospermum (Manuka) honey exerts antimicrobial effects through high hyperosmolarity, an acidic pH (3.2-4.5), and continuous low-level hydrogen peroxide generation.
Topical antimicrobial dressing regimens should be evaluated within 2 to 4 weeks; if bioburden is controlled, treatment should be discontinued to prevent tissue toxicity and cellular resistance.
Last updated: August 2026
Antimicrobial & Biofilm Dressings: Silver, Cadexomer Iodine, and Honey
Bacterial bioburden and mature bacterial biofilms represent primary barriers to chronic wound healing. When bacteria transition from free-floating (planktonic) organisms to sessile communities encased within an Extracellular Polymeric Substance (EPS) matrix, their resistance to host immune defenses and systemic antibiotics increases by 100- to 1000-fold . Managing critical colonization and biofilm requires specialized topical antimicrobial agents. The three primary evidence-based antimicrobial dressing technologies utilized in wound care are ionic silver , cadexomer iodine , and medical-grade honey .
Bioburden Assessment: NERDS & STONEES Criteria
Clinicians must distinguish between localized wound infection (critically colonized / biofilm) and deep tissue / systemic infection to select appropriate topical vs. systemic therapies. LOCALIZED INFECTION / BIOFILM (NERDS) DEEP / SYSTEMIC INFECTION (STONEES)
- +-----------------------------------------+ +-----------------------------------------+
- | N - Non-healing wound | | S - Size increasing |
- | E - Exudate increased | | T - Temperature elevated (local/systemic|
- | R - Red & bleeding granulation tissue | | O - Os (Probe to bone positive) |
- | D - Debris & slough on wound bed | | N - New areas of breakdown |
- | S - Smell / Fetid odor | | E - Exudate, Erythema, & Edema |
- +-----------------------------------------+ +-----------------------------------------+
- | |
- v v
- [ TOPICAL ANTIMICROBIAL DRESSINGS ] [ SYSTEMIC ANTIBIOTICS + TOPICAL ]
- (Silver, Cadexomer Iodine, Honey) (Requires urgent medical intervention)
- 1. Silver-Impregnated Dressings
- Mechanism of Action of Ionic Silver ( A g + Ag^+ A g + )
Metallic silver ( A g 0 Ag^0 A g 0 ) is biologically inactive. To exert antimicrobial activity, silver must be oxidized by wound fluid into bioactive ionic silver ( A g + Ag^+ A g + ) . A g + Ag^+ A g + ions exhibit a broad-spectrum bactericidal mechanism involving three distinct cellular targets:
Cell Membrane Damage: A g + Ag^+ A g + binds to bacterial cell membrane proteins and peptidoglycan cell walls, increasing membrane permeability, causing proton leakage, and inducing cell lysis.
Enzymatic Inhibition: A g + Ag^+ A g + binds to sulfhydryl ( − S H -SH − S H ) groups on metabolic and respiratory enzymes within the bacterial cytoplasm, inhibiting cellular respiration and ATP synthesis.
DNA/RNA Disruption: A g + Ag^+ A g + enters the cell and intercalates with bacterial DNA and RNA, preventing cell replication and transcription.
Formulations & Wear Time
Silver is incorporated into alginates, hydrofibers, foams, and nanocrystalline polyethylene mesh dressings. Nanocrystalline silver formulations maintain a continuous release of A g + Ag^+ A g + ions (at ~70–100 ppm) over 3 to 7 days . SILVER ION (Ag+) MULTI-TARGET BACTERICIDAL MECHANISM
- [ Ag+ Ion Release ]
- / | \
- / | \
- v v v
- [ Cell Membrane ] [Enzymes] [Bacterial DNA]
- Binds peptidoglycans Denatures Intercalates bases;
- & induces lysis -SH groups; stops replication
- halts ATP
Clinical Application Rules & Precautions:
Two to Four-Week Rule: Topical silver should be used for a trial period of 2 to 4 weeks . If bioburden is controlled, step down to a non-antimicrobial dressing. Prolonged unnecessary use risks localized tissue toxicity to host fibroblasts and keratinocytes.
Contraindications: Patient hypersensitivity to silver; contraindicated prior to Magnetic Resonance Imaging (MRI) if using metallic nanocrystalline mesh (causes artifact or thermal heating).
Inactivation: Avoid combining ionic silver with sodium chloride (saline) wound flushes if precipitation of silver chloride ( A g C l AgCl A g Cl ) occurs, which reduces free A g + Ag^+ A g + bioavailability.
Loading diagram... Biofilm Disruption Mechanism of Cadexomer Iodine
- 2. Cadexomer Iodine Dressings
- Structure & Biofilm Disruption Technology
Cadexomer iodine is a specialized formulation composed of 3D spherical micro-beads of cross-linked carboxymethylcellulose starch containing 0.9% elemental iodine physically trapped within the bead lattice.
Dual-Action Mechanism:
Physical Fluid & Biofilm Absorption: As exudate enters the cadexomer micro-beads, they swell, drawing in wound fluid, exudate proteins, and free bacteria.
Sustained Non-Cytotoxic Iodine Release: Swelling causes the micro-beads to slowly release low concentrations of free elemental iodine directly into the wound bed over 48 to 72 hours .
Unlike traditional povidone-iodine (which releases high toxic bursts of iodine that damage host fibroblasts), cadexomer iodine maintains a low, non-cytotoxic iodine concentration. Crucially, cadexomer iodine is one of the few topical agents clinically proven to penetrate and disrupt mature bacterial EPS biofilm matrix , killing embedded Staphylococcus aureus and Pseudomonas aeruginosa .
Application Limits & Safety Boundaries:
Maximum Single Application: No more than 50 grams of cadexomer iodine gel/pad per single application.
Maximum Weekly Limit: No more than 150 grams total per week.
Maximum Treatment Duration: Continuous treatment must not exceed 3 months .
Contraindications: Thyroid disease (Graves' disease, Hashimoto's thyroiditis, thyroid nodules), iodine hypersensitivity, pregnant or lactating women, and patients receiving lithium therapy.
- 3. Medical-Grade Honey (Leptospermum / Manuka)
- Composition & Standard Requirements
Medical-grade honey is derived exclusively from the nectar of the Leptospermum plant species (Manuka honey). It is sterilized via gamma irradiation to destroy bacterial endospores ( Clostridium botulinum ) while preserving delicate bio-active enzymes.
Triple Antimicrobial Mechanism of Action:
High Hyperosmolarity: High sugar content (80% carbohydrates) creates high osmotic pressure. Water is drawn out of bacterial cells via osmosis, inducing bacterial plasmolysis and cell death.
Acidic pH (3.2 to 4.5): Creates a low pH environment that inhibits pathogenic growth while accelerating macrophage activity, fibroblast migration, and oxygen release from hemoglobin (Bohr effect).
Phytochemical Methylglyoxal (MGO) & Hydrogen Peroxide: Endogenous glucose oxidase enzymes produce low, continuous levels of H 2 O 2 H_2O_2 H 2 O 2 . In addition, Manuka honey contains high levels of Methylglyoxal (MGO) , providing potent non-peroxide antibacterial activity. TRIPLE ANTIMICROBIAL ACTION OF LEPTOSPERMUM HONEY
- +-------------------------------------------------------------------------+
- | 1. HYPEROSMOLARITY (Draws water from bacterial cells -> Plasmolysis) |
- +-------------------------------------------------------------------------+
- | 2. LOW pH (3.2 - 4.5) (Inhibits pathogens; optimizes macrophage/MMPs) |
- +-------------------------------------------------------------------------+
- | 3. MGO & H2O2 PRODUCTION (Continuous phytochemical bactericidal effect) |
- +-------------------------------------------------------------------------+
Additional Clinical Benefits:
Rapid Malodor Reduction: Bacteria utilize honey glucose rather than amino acids, eliminating volatile sulfur and ammonia odor compounds within 24 hours.
Autolytic Debridement: High osmotic fluid draw pulls lymph fluid from deep tissue up to the wound surface, softening necrotic slough.
Stinging Sensation: Clinicians must counsel patients that a transient stinging sensation may occur upon application due to low pH and fluid shifts.
Comprehensive Antimicrobial Dressing Comparison
Active Agent Primary Mechanism Biofilm Efficacy Typical Wear Time Key Dosing / Duration Limit Major Contraindications
Ionic Silver ( A g + Ag^+ A g + ) Cell wall lysis, enzyme denaturing, DNA binding Moderate (Planktonic focus) 3 to 7 days Reassess at 2 to 4 weeks Silver allergy, pre-MRI
Cadexomer Iodine Sustained 0.9% iodine release via starch beads Superior (Penetrates EPS) 48 to 72 hours Max 50g/app; 150g/wk; 3 months Thyroid disease, pregnancy, lithium
Medical Honey Hyperosmolarity, pH 3.2-4.5, MGO & H 2 O 2 H_2O_2 H 2 O 2 High (Autolysis + EPS clearance) 1 to 3 days None established Honey/bee venom allergy